Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TACOMA, Wash., July 18, 2013 /PRNewswire/ -- On Wednesday Revalesio Corporation presented new data at the Alzheimer’s Association International Conference that identifies the specific cellular pathways by which Revalesio’s lead investigational product, RNS60, impacts Alzheimer’s Disease. This research, conducted in partnership with Rush University Medical Center, investigates a new category of therapeutics using Revalesio’s novel nanotechnology platform.
Data presented at the conference demonstrated RNS60’s ability to prevent memory loss and improve learning through the PI3k-pAKT pathway. Additionally, RNS60 upregulates critical genes associated with neuronal plasticity. These genes play a key role in healthy neurotransmitter and synaptic function, foundational activities of the brain.
Defining RNS60’s activity against these genes is an important link between the significant therapeutic activity demonstrated by RNS60 in mouse and cellular models where RNS60 prevented beta-amyloid induced cell death and tau-neurofibrillary tangles the most common hallmarks of Alzheimer’s disease.
“The ability to define RNS60’s biological activity to these plasticity associated genes and the PI3k-pAKT-CREB-BDNF pathway is an important event for the company,” said Dr. Richard Watson, Revalesio’s Chief Science Officer. “We have a large and expanding data set on RNS60’s ability to reduce inflammation, and these findings are a significant advancement in our understanding of how RNS60 may be a treatment for neuro-degenerative diseases.”
These plasticity associated genes and associated pathways have long been targets for drug developers, but Revalesio’s approach through its charge-stabilized nanostructure technology provides a new paradigm for treating Alzheimer’s disease. Revalesio and its research partners at Rush University Medical Center have submitted the data for publication.
About RNS60
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects voltage-sensing membrane-bound proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases. RNS60 has successfully completed Phase I safety studies and is advancing into Phase II clinical trials.
About Revalesio Corporation
Revalesio is a pioneering-clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world to develop RNS60. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.
Press Contact:
Jesse Thomas
253-926-5567
Email
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.
SOURCE Revalesio Corporation
Help employers find you! Check out all the jobs and post your resume.
